- New in vitro results highlight the ability of Hilucia™ for Pets ingredients to support inflammation resolution in dogs, opening new opportunities for functional pet food formulations
Paris, May 11, 2026 – Ahead of Interzoo 2026, Innovafeed, in collaboration with Ambiotis, leader in inflammation resolution mechanisms, announces promising new results demonstrating the anti-inflammatory potential of its ingredient Hilucia™ for Pets.
As pet health becomes an increasing priority for pet owners, veterinarians, and brands, managing inflammation is a key challenge. Chronic inflammation is associated with a wide range of conditions in dogs and cats, including skin disorders, digestive issues, joint diseases, and reduced overall well-being.
A targeted and innovative mechanism to support inflammation resolution
In an in vitro study conducted on a canine whole blood model, the hydrosoluble fraction of Hilucia™ for Pets showed a unique and selective modulation of cytokine secretion, a key mechanism in the body’s inflammatory response.
Key findings include:
- Reduction of TNF-α, a major pro-inflammatory cytokine, to levels comparable to dexamethasone, a reference anti-inflammatory compound
- Increase of IL-10, a critical anti-inflammatory cytokine involved in resolving inflammation
- Selective regulation of cytokines, unlike conventional anti-inflammatory compounds that suppress all cytokine secretions
This dual action suggests that Hilucia™ for Pets does not simply inhibit inflammation but actively supports its resolution, a critical physiological process to restore balance while maintaining immune function.
A new generation of functional ingredients for pet health
These results reinforce the positioning of Hilucia™ for Pets as a functional ingredient with tangible health benefits, particularly relevant for:
- Sensitive diets
- Skin and coat health
- Digestive health
- Joint support and mobility
- Weight management
By combining bioactive peptides and naturally occurring compounds, the ingredient offers a science-backed solution to address key health challenges in pets through nutrition.
Industry collaboration driving innovation
The study was conducted by Ambiotis, leveraging its expertise in inflammation biology and translational research.
“The resolution of inflammation is a key physiological process that restores tissue balance while maintaining immune system effectiveness. Through its dual modulation of cytokines—stimulating IL-10 and inhibiting TNF-α—Hilucia™ provides an innovative mechanism of action that naturally activates the body’s own pathways for resolving inflammation.”
Gérald Chêne, Head of Laboratory at Ambiotis
From science to scalable solutions
These findings illustrate Innovafeed’s ambition to go beyond sustainability and deliver ingredients with measurable health benefits for pets.
“This study marks an important milestone in demonstrating that insect-based ingredients can play a functional role in pet health. With our Hilucia™ for Pets range, we are introducing a new generation of solutions that combine performance, science, and sustainability,”
Amélie Maurice, R&D Engineer at Innovafeed
Meet us at Interzoo 2026
Innovafeed will be showcasing its latest innovations in pet nutrition, including Hilucia™ for Pets, at Interzoo 2026: Hall 1 – Booth 522.
Download our Whitepaper: https://innovafeed.com/en/hilucia-pets/?popup=6971
Media contact Innovafeed
Nadège Audiffren, Innovafeed
Head of Global Communications
- 33 6 64092594
nadege.audiffren@innovafeed.com
